keyword
MENU ▼
Read by QxMD icon Read
search

antiretroviral drugs

keyword
https://www.readbyqxmd.com/read/29781356/combating-the-hiv-reservoirs
#1
Guido van Marle, Deirdre L Church, Frank van der Meer, M John Gill
Impressive advances have been made in the treatment and management of HIV-1 infected individuals. Combination antiretroviral therapy (cART) has turned HIV-1 infection from an almost invariable deadly infectious disease, to a lifelong manageable infectious disease. However, a cure or vaccine has not been forthcoming. A major problem in HIV-1 infection is the persistent and latently infected cellular and tissue reservoirs. One of these reservoirs is the Gut Associated Lymphoid tissue (GALT), which has been the research focus of our group...
May 21, 2018: Biotechnology & Genetic Engineering Reviews
https://www.readbyqxmd.com/read/29778557/nanotechnological-foundations-of-a-%C3%A2-new%C3%A2-nephrology
#2
M Laura Sorian, Alberto Rodríguez-Benot, Miguel Valcárcel
After contextualising the generic frameworks of nanotechnology and nanomedicine, the 2disciplines are discussed in the field of Nephrology. The potential downside to nanonephrology is the renal clearance of nanoparticles, the use of which is ever-increasing both for nanomedicinal purposes and in nanofoods. The positive impact of nanotechnology in Nephrology is centred on the development of renal nanodiagnostics for basic renal function studies, the early diagnosis of acute kidney injury, reliable and simple follow-up of chronic kidney disease and the improvement of magnetic resonance imaging...
May 16, 2018: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
https://www.readbyqxmd.com/read/29778137/deciphering-natural-control-of-hiv-1-a-valuable-strategy-to-achieve-antiretroviral-therapy-termination
#3
REVIEW
Hamza Loucif, Steven Gouard, Xavier Dagenais-Lussier, Armstrong Murira, Simona Stäger, Cécile Tremblay, Julien Van Grevenynghe
Antiretroviral therapy (ART) has dramatically reduced HIV-1-associated morbidity and mortality, and has transformed HIV-1 infection into a manageable chronic condition by suppressing viral replication. However, despite recent patient care improvements, ART still fails to cure HIV-1 infection due to the inability to counteract immune defects and metabolic disturbances that are associated with residual inflammation alongside viral persistence. Life-long drug administration also results in multiple side-effects in patients including lipodystrophy and insulin resistance...
April 2018: Cytokine & Growth Factor Reviews
https://www.readbyqxmd.com/read/29777923/diagnosis-and-management-of-pulmonary-infection-due-to-rhodococcus-equi
#4
REVIEW
Weijie V Lin, Robert L Kruse, Katharine Yang, Daniel M Musher
BACKGROUND: Rhodococcus equi is a recognized cause of disease in humans, especially in patients who are immunocompromised. Because diphtheroids are regarded as part of normal respiratory flora, the importance of R. equi as a pulmonary pathogen may not be fully appreciated and its prevalence underestimated. Most treatment recommendations for R. equi infection were established before antiretroviral drugs became available for HIV/AIDS therapy, and therapeutic strategies may need to be updated...
May 16, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29775551/pharmacogenetic-associations-with-cytochrome-p450-in-antiretroviral-therapy-what-does-the-future-hold
#5
Gabriel Stillemans, Leila Belkhir, Dennis A Hesselink, Vincent Haufroid, Laure Elens
Several antiretroviral drugs used to treat infection with the Human Immunodeficiency Virus (HIV) are substrates of enzymes belonging to the cytochrome P450 (CYP) superfamily, which are polymorphically expressed. It may therefore be useful to take into account the genetic variation in these enzymes to predict the likelihood of anti-HIV treatment success, toxicity and the potential for drug-drug interactions. Areas covered: In this manuscript, the authors discuss the current state of knowledge regarding pharmacogenetic associations between CYP and all major antiretrovirals, as well as the importance of these associations...
May 18, 2018: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29775399/dolutegravir-and-rilpivirine-for-the-maintenance-treatment-of-virologically-suppressed-hiv-1-infection
#6
Jose L Casado, Marta Monsalvo, Aurora M Rojo, María Fontecha, Miguel A Rodriguez-Sagrado
Triple combinations of antiretroviral (ART) drugs are the standard treatment for HIV infection, but the challenges include long-term side effects, high costs, and adherence. The recent advent of potent and well tolerated ART has renewed the interest for newer ART strategies. A dual regimen with the combination of dolutegravir (DTG) and rilpivirine (RPV), two well tolerated, metabolic-friendly, and potent drugs could offer additional benefits. Areas covered: A review of recent randomized trials and observational cohorts concerning the use of a dual therapy with DTG plus RPV as a switching strategy in patients with viral suppression...
May 18, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29771783/hiv-1-drug-resistance-among-ugandan-adults-attending-an-urban-out-patient-clinic
#7
Amrei von Braun, Christine Sekaggya-Wiltshire, Nadine Bachmann, Deogratius Ssemwanga, Alexandra U Scherrer, Maria Nanyonjo, Anne Kapaata, Pontiano Kaleebu, Huldrych F Günthard, Barbara Castelnuovo, Jan Fehr, Andrew Kambugu
BACKGROUND: Little is known about prevalence of drug resistance among HIV-infected Ugandans, a setting with over 15 years of public-sector access to antiretroviral therapy (ART) and where virological monitoring was only recently introduced. SETTING: This study was conducted in the adults' out-patient clinic of the Infectious Diseases Institute, Kampala, Uganda. METHODS: HIV genotyping was performed in ART naïve patients and in treatment experienced patients on ART for ≥ six months with virological failure (≥1000 copies/mL)...
April 27, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29771694/fostemsavir-a-new-cd4-attachment-inhibitor
#8
Pedro Cahn, Valeria Fink, Patricia Patterson
PURPOSE OF REVIEW: Even in the era of modern HAART, antiretroviral (ARV) failure and emergence of drug resistance is still a problem worldwide. New classes with different mechanisms of action are needed to overcome this challenge. After the integrase inhibitors were launched, more than a decade ago, no new classes were added to the ARV armamentarium. RECENT FINDINGS: Fostemsavir (FTR) is an attachment inhibitor, active regardless of viral tropism, without cross-resistance to any of the existing ARV compounds...
May 15, 2018: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/29769566/antiretroviral-drugs-alter-the-content-of-extracellular-vesicles-from-hiv-1-infected-cells
#9
Catherine DeMarino, Michelle L Pleet, Maria Cowen, Robert A Barclay, Yao Akpamagbo, James Erickson, Nicaise Ndembe, Manhattan Charurat, Jibreel Jumare, Sunday Bwala, Peter Alabi, Max Hogan, Archana Gupta, Nicole Noren Hooten, Michele K Evans, Benjamin Lepene, Weidong Zhou, Massimo Caputi, Fabio Romerio, Walter Royal, Nazira El-Hage, Lance A Liotta, Fatah Kashanchi
To date, the most effective treatment of HIV-1 is a combination antiretroviral therapy (cART), which reduces viral replication and reverses pathology. We investigated the effect of cART (RT and protease inhibitors) on the content of extracellular vesicles (EVs) released from HIV-1-infected cells. We have previously shown that EVs contain non-coding HIV-1 RNA, which can elicit responses in recipient cells. In this manuscript, we show that TAR RNA levels demonstrate little change with the addition of cART treatment in cell lines, primary macrophages, and patient biofluids...
May 16, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29769116/efficacies-of-cabotegravir-and-bictegravir-against-drug-resistant-hiv-1-integrase-mutants
#10
Steven J Smith, Xue Zhi Zhao, Terrence R Burke, Stephen H Hughes
BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are the class of antiretroviral (ARV) drugs most recently approved by the FDA for the treatment of HIV-1 infections. INSTIs block the strand transfer reaction catalyzed by HIV-1 integrase (IN) and have been shown to potently inhibit infection by wild-type HIV-1. Of the three current FDA-approved INSTIs, Dolutegravir (DTG), has been the most effective, in part because treatment does not readily select for resistant mutants. However, recent studies showed that when INSTI-experienced patients are put on a DTG-salvage therapy, they have reduced response rates...
May 16, 2018: Retrovirology
https://www.readbyqxmd.com/read/29767681/drug-side-effects-and-retention-on-hiv-treatment-a-regression-discontinuity-study-of-tenofovir-implementation-in-south-africa-and-zambia
#11
Alana T Brennan, Jacob Bor, Mary-Ann Davies, Gilles Wandeler, Hans Prozesky, Geoffrey Fatti, Robin Wood, Kathryn Stinson, Frank Tanser, Till Bärnighausen, Andrew Boulle, Izukanji Sikazwe, Arianna Zanolini, Matthew P Fox
Tenofovir is less toxic than other nucleoside reverse transcriptase inhibitors used in antiretroviral therapy (ART) and may improve retention of HIV-infected patients on ART. We assessed the impact of national guideline changes in South Africa (2010) and Zambia (2007) recommending tenofovir in first-line ART. We applied regression discontinuity in a prospective cohort of 52,294 HIV-infected adults initiating first-line ART within ±12-months of each guideline change. We compared outcomes in patients presenting just before/after the guideline changes using local linear regression and estimated intention-to-treat effects on initiation of tenofovir, retention in care, and other treatment outcomes at 24-months...
May 15, 2018: American Journal of Epidemiology
https://www.readbyqxmd.com/read/29767640/burden-of-exposure-to-potential-interactions-between-antiretroviral-and-non-antiretroviral-medications-in-a-population-of-hiv-positive-patients-aged-50-years-or-older
#12
Alice Ranzani, Letizia Oreni, Massimiliano Agrò, Lorena van den Bogaart, Laura Milazzo, Andrea Giacomelli, Dario Cattaneo, Cristina Gervasoni, Anna Lisa Ridolfo
BACKGROUND: As HIV-infected patients aged 50 years or older are at increased risk of comorbidities and multidrug treatments, we examined their exposure to the potential drug-drug interactions (PDDIs) of antiretroviral (ARV) and other medications. METHODS: This cross-sectional study involved the patients aged 50 years or older receiving ARV and non-ARV medications at our clinic. PDDIs were identified using the University of Liverpool HIV Drug Interaction Checker...
June 1, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29767543/efficacy-of-single-tablet-darunavir-cobicistat-emtricitabine-and-tenofovir-alafenamide-in-the-treatment-of-hiv-1
#13
Eugènia Negredo, Bonaventura Clotet
HIV eradication is not feasible and lifelong treatment is warranted to manage HIV infection. In this scenario, the advent of single-tablet, once-daily, fixed-dose co-formulations is important for reducing pill burden and maximize long-term drug adherence. Cobicistat-boosted darunavir along with emtricitabine and tenofovir alafenamide co-formulation (DRV/c/FTC/TAF or the trade name Symtuza®) is the first marketed protease inhibitor-based fixed-dose combination regimen for the treatment of HIV infection. It was approved in late 2017 by the European Medical Agency both for naïve patients and treatment-experienced patients with viral suppression...
May 16, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29766745/incidence-of-acute-kidney-injury-in-patients-co-infected-with-hiv-and-hepatitis-c-virus-receiving-tenofovir-disoproxil-fumarate-and-ledipasvir-sofosbuvir-in-a-real-world-urban-ryan-white-clinic
#14
Jessica L Michal, Saira Rab, Manish Patel, Alison Kyle, Lesley Miller, Kirk A Easley, Aley Kalapila
Background Ledipasvir/sofosbuvir (LDV/SOF), an antiviral treatment for hepatitis C virus (HCV), and tenofovir disoproxil fumarate (TDF), an antiretroviral for treating human immunodeficiency virus (HIV), may be co-administered in patients co-infected with these viruses. A drug interaction between LDV and TDF could increase TDF-associated nephrotoxicity rates; however, there is minimal clinical evidence describing acute kidney injury (AKI) rates in this population. Setting This study was conducted at a Ryan White-funded facility in Atlanta, Georgia, that cares for over 5,000 patients with AIDS...
May 16, 2018: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/29765441/suspected-unexpected-and-other-adverse-reactions-to-antiretroviral-drugs-used-as-post-exposure-prophylaxis-of-hiv-infection-five-year-experience-from-clinical-practice
#15
Justyna D Kowalska, Ewa Pietraszkiewicz, Ewa Firląg-Burkacka, Andrzej Horban
Introduction: With increased use of antiretroviral drugs (ARVs) in HIV uninfected persons, proper reporting on suspected unexpected serious adverse reactions (SUSARs) and continued insight into adverse drug reactions (ADRs) are needed for adequate information on safety of ARVs in such populations. Material and methods: Medical documentation of persons receiving ARVs after non-occupational HIV exposure (non-occupational post-exposure prophylaxis - nPEP) during 5 successive years (2009-2013) was evaluated by two HIV physicians...
April 2018: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/29765082/pretreatment-drug-resistance-in-a-large-countrywide-ethiopian-hiv-1c-cohort-a-comparison-of-sanger-and-high-throughput-sequencing
#16
Nigus Fikrie Telele, Amare Worku Kalu, Solomon Gebre-Selassie, Daniel Fekade, Samir Abdurahman, Gaetano Marrone, Ujjwal Neogi, Belete Tegbaru, Anders Sönnerborg
Baseline plasma samples of 490 randomly selected antiretroviral therapy (ART) naïve patients from seven hospitals participating in the first nationwide Ethiopian HIV-1 cohort were analysed for surveillance drug resistance mutations (sDRM) by population based Sanger sequencing (PBSS). Also next generation sequencing (NGS) was used in a subset of 109 baseline samples of patients. Treatment outcome after 6- and 12-months was assessed by on-treatment (OT) and intention-to-treat (ITT) analyses. Transmitted drug resistance (TDR) was detected in 3...
May 15, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29763698/engineered-mixed-oxide-based-polymeric-composites-for-enhanced-antimicrobial-activity-and-sustained-release-of-antiretroviral-drug
#17
Mosab Ali Abureesh, Akeem Adeyemi Oladipo, Zirar M Mizwari, Ersan Berksel
Here, pH-responsive engineered polymeric composites were fabricated from sodium alginate and mixed Cu/Zn oxides. The resulting alginate-Cux Zn1-x O composites were characterized by FTIR, SEM and XRD, then used as an efficient carrier for the antiretroviral drug (zidovudine, AZT) and exhibited remarkable antibacterial properties. The resulting polymeric composites had specific surface areas of 185.2-198.6 m2 /g as confirmed by the Brunauer-Emmett-Teller analysis. The metal oxide distribution within the alginate matrix was confirmed from the X-ray diffraction and scanning electron microscopy analyses...
May 12, 2018: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/29762344/use-of-nonantiretroviral-medications-that-may-impact-neurocognition-patterns-and-predictors-in-a-large-long-term-hiv-cohort-study
#18
Kendra K Radtke, Peter Bacchetti, Kathryn Anastos, Daniel Merenstein, Howard Crystal, Roksana Karim, Kathleen M Weber, Andrew Edmonds, Anandi N Sheth, Margaret A Fischl, David Vance, Ruth M Greenblatt, Leah H Rubin
BACKGROUND: Neurocognitive impairment is a frequent and often disabling comorbidity of HIV infection. In addition to antiretroviral therapies, individuals with HIV infection may commonly use nonantiretroviral medications that are known to cause neurocognitive adverse effects (NC-AE). The contribution of NC-AE to neurocognitive impairment is rarely considered in the context of HIV and could explain part of the variability in neurocognitive performance among individuals with HIV. SETTING: Women's Interagency HIV Study, a prospective, multisite, observational study of US women with and without HIV...
June 1, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29762171/hiv-transmission-in-discordant-couples-in-africa-in-the-context-of-art-availability
#19
Evonne Woodson, Alec Goldberg, Clive Michelo, Debby Basu, Sijia Tao, Raymond Schinazi, Yong Jiang, William Kilembe, Etienne Karita, Susan Allen, Eric Hunter
OBJECTIVE: This study aims to understand the basis of continued HIV-1 transmission in Zambian and Rwandan HIV-1 discordant couples in the context of ART. DESIGN: We identified 9 Zambian and 7 Rwandan acutely-infected, epidemiologically-linked couples from government CVCT clinics where transmitting partners reported being on ART near the time of transmission. METHODS: We quantified viral load (VL) and plasma antiretroviral (ARV) drug concentrations near the time of transmission and used these as surrogate measures for adherence...
May 11, 2018: AIDS
https://www.readbyqxmd.com/read/29762166/undisclosed-antiretroviral-drug-use-in-botswana-implication-for-national-estimates
#20
Sikhulile Moyo, Simani Gaseitsiwe, Kathleen M Powis, Molly Pretorius Holme, Terence Mohammed, Melissa Zahralban-Steele, Etienne K Yankinde, Comfort Maphorisa, William Abrams, Refeletswe Lebelonyane, Kutlo Manyake, Tumalano Sekoto, Mompati Mmalane, Tendani Gaolathe, Kathleen E Wirth, Joseph Makhema, Shahin Lockman, William Clarke, Max Essex, Vlad Novitsky
: Among 3596 HIV-positive participants enrolled in Botswana Combination Prevention Project who self-reported no prior antiretroviral (ARV) therapy use and were tested for viral load (n = 951; 27% of all participants), 136 (14%) had HIV-1 RNA less than 400 copies/ml. ARV drugs were detected in 52 (39%) of 134 participants tested. Adjusting for undisclosed ARV use increased the overall estimate of virally suppressed individuals on ARV therapy by 1.4% from 70.2 to 71.6%.
May 11, 2018: AIDS
keyword
keyword
96048
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"